Camrelizumab combined with platinum-free single-agent chemotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a prospective, single-arm, exploratory study
Cancer Treatment and Research Communications · 2026-10 · 101508
DOI: 10.1016/j.ctarc.2026.101508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026-10. Verfasst von Lianmin Zhang und 9 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
The present study aimed to investigate the efficacy and safety of camrelizumab plus platinum-free single-agent chemotherapy in patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). Materials and Methods The present prospective, single-arm, exploratory study enrolled patients with early-stage, medically inoperable NSCLC to receive camrelizumab (200 mg, intravenously, day 1) camrelizumab plus platinum-free single-agent chemotherapy in a 3-week cycle for 4-6 cycles, followed by camrelizumab maintenance therapy for less than 1 year. The primary endpoint was progression-free survival (PFS). The secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
Between October 19, 2020, and December 19, 2023, a total of 21 patients were enrolled in this study and the median follow-up time was 25.9 months (range: 12.8-35.1 months). The confirmed best ORR was 28.6% (95% CI, 11.3-52.2) and the confirmed best DCR was 95.2% (95% CI, 76.2-99.9). The median PFS and the median OS of patients in the full analysis set were 15.1 months (95% CI, 11.0-35.6) and 35.6 months (95% CI, 25.5-NE), respectively. In patients aged 65 years or older, the median PFS and the median OS were 30.5 months (95%CI, 8.3-35.6) and not reached. In the safety analysis set, 5 patients (23.8%) experienced grade ≥3 treatment-related adverse events (TRAEs), and 4 patients (19.0%) experienced ≥3 immune-related AEs.
Conclusion
Camrelizumab plus platinum-free single-agent chemotherapy showed modest antitumor activity in patients with early-stage, medically inoperable NSCLC. These exploratory findings require confirmation in larger, controlled studies.
Zitieren
APA
Zhang, L., Zhang, Z., Li, Y., Zhang, L., Zhao, X., Zhang, Q., Li, C., Wang, M., Yue, D., & Wang, C. (2026). Camrelizumab combined with platinum-free single-agent chemotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a prospective, single-arm, exploratory study. Cancer Treatment and Research Communications, 101508. https://doi.org/10.1016/j.ctarc.2026.101508
Vancouver
Zhang L, Zhang Z, Li Y, Zhang L, Zhao X, Zhang Q, et al. Camrelizumab combined with platinum-free single-agent chemotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a prospective, single-arm, exploratory study. Cancer Treatment and Research Communications. 2026:101508. doi:10.1016/j.ctarc.2026.101508
BibTeX
@article{Zhang2026,
author = {Zhang, Lianmin and Zhang, Zhenfa and Li, Yue and Zhang, Lei and Zhao, Xiaoliang and Zhang, Qiang and Li, Chenguang and Wang, Meng and Yue, Dongsheng and Wang, Changli},
title = {Camrelizumab combined with platinum-free single-agent chemotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a prospective, single-arm, exploratory study},
journal = {Cancer Treatment and Research Communications},
year = {2026},
pages = {101508},
doi = {10.1016/j.ctarc.2026.101508}
}
EUVIMED